Total trials
209
Active
60
Phase 3
4
Total enrollment
587,099
Pipeline matrix
Showing 13 of 13 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tirzepatide | — | — | — | — | — | 1 | |
| Stibium metallicum praeparatum 6x | — | — | — | — | — | 1 | |
| Epirubicin | — | — | — | — | — | 1 | |
| Mitomycin | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Cannabis | — | — | — | — | — | 1 | |
| Fluoxetine | — | — | — | — | — | 1 | |
| Sertraline Pill | — | — | — | — | — | 1 | |
| Regulated cannabis from authorized pharmacies | — | — | — | — | — | 1 | |
| Cannabis from the illicit market | — | — | — | — | — | 1 | |
| PRF as adjunct to non-surgical mechanical debridement | — | — | — | — | — | 1 | |
| Control, non-surgical mechanical debridement alone | — | — | — | — | — | 1 |
Next readouts
- 2026-06
- 2026-06-19
- 2026-09-30
- 2026-10
- 2027-12-24
- 2027-12-28
- 2028-08
Top conditions
- Smoking Cessation12
- Healthy9
- Mild Cognitive Impairment7
- Exposure to Man-made Visible Light7
- Alzheimer Disease6
- Suicidal Ideation5
- Dental Implant Failed5
- Childhood Cancer5
Frequently asked questions about University of Bern
- How many clinical trials does University of Bern have on ClinicalTrials.gov?
- University of Bern is listed as the lead sponsor on 209 clinical trials in ClinicalTrials.gov, 60 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Bern's trials are in Phase 3?
- 4 of University of Bern's trials are in Phase 3, spread across 13 active drug programs.
- What therapeutic areas does University of Bern focus on?
- University of Bern's most-studied conditions on ClinicalTrials.gov are Smoking Cessation, Healthy, Mild Cognitive Impairment, Exposure to Man-made Visible Light, Alzheimer Disease.
- When are University of Bern's next clinical trial readouts?
- University of Bern has 7 upcoming primary-completion readouts tracked here; the soonest is “GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes”, expected around 2026-06.